Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D for Sickle-cell Respiratory Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of sickle cell disease (HbSS, HbSC, HbS Beta-thalassemia)~* Age 3 to 20 years old~Exclusion Criteria:~* Patient (or parent or guardian) unwilling or unable to provide written informed consent (and assent, if applicable)~* Patient unable or unwilling to comply with requirements of the clinical trial~* Participation in other therapeutic clinical trial~* Current diagnosis of rickets~* History of hypercalcemia or diagnosis of any medical condition associated with hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis, tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia~* Current use of corticosteroids, excluding inhaled steroids~* Current use of anticonvulsants (phenytoin, phenobarbital, carbamazepine)~* Therapy with thiazide diuretics or lithium carbonate~* Known liver or renal disease~* Patients taking medications for pulmonary complications of sickle cell disease not on a stable dose of medications, as defined by a change in medications or doses within the three months prior to study entry~* Patients on chronic red blood cell transfusion therapy~* Absence of baseline record of respiratory events (respiratory infections, asthma exacerbations, episodes of acute chest syndrome) for the preceding year~* Pregnancy

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 100,000 IU (Type: EXPERIMENTAL): Oral vitamin D3, 100,000 IU \[2.5 mg\] given once a month
- Vitamin D3 12,000 IU (Type: ACTIVE_COMPARATOR): Standard dose oral vitamin D3 12,000 IU \[0.3 mg\] given once a month

Based on this trial design, predict the completion outcome and termination type (if applicable).